
|Videos|November 15, 2013
Hepatitis C: Patient Warehousing
Aimee Tharaldson of Express Scripts explains why some hepatitis C patients who do not have signs of active disease may want to wait to receive treatment until later this year and early next year, when the FDA is expected to approve sofosbuvir and simeprevir for the treatment of this condition.
Advertisement
Aimee Tharaldson of Express Scripts explains why some hepatitis C patients who do not have signs of active disease may want to wait to receive treatment until later this year and early next year, when the FDA is expected to approve sofosbuvir and simeprevir for the treatment of this condition.
This video was shot at the 2013 Academy of Managed Care Pharmacy Nexus meeting in San Antonio, Texas.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First OTC Acetaminophen–Naproxen Combination for 12-Hour Pain Relief
2
Two Weeks In: What the Medicare GLP-1 Bridge Actually Looks Like at the Counter
3
Thoracic Radiotherapy Added to Atezolizumab Raises Fatal Toxicity Risk in ES-SCLC
4
Up to 5 Cups of Coffee Daily Safe—and Beneficial—for Most Adults
5










































































































